$IDXG SEC Filings

Filed On	Filing
15 Oct 2026	FWP
15 Oct 2026	8-K: Results of Operations and Financial Condition Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
01 Oct 2026	S-1/A
25 Sep 2026	S-1
17 Sep 2026	S-8
27 Aug 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure
26 Aug 2026	8-K/A: Departure/Election of Directors or Officers; Compensation
21 Aug 2026	8-K: Submission of Matters to a Vote of Security Holders
20 Aug 2026	Form 4: Burnell Thomas W., Director Received 1,966,763 shares by exercise or conversion · Gave up 581,718 shares to cover exercise price or tax ($937K) · Granted 1,966,763 Restricted Stock Units · 1 more
20 Aug 2026	Form 4: Aggarwal Vijay, Director Granted 69,252 Restricted Stock Units
20 Aug 2026	Form 4: Rocca Fortunato R., Director Granted 69,252 Restricted Stock Units
20 Aug 2026	Form 4: Keegan Joseph D, Director Granted 69,252 Restricted Stock Units
20 Aug 2026	Form 4: Sullivan Stephen J, Director Granted 69,252 Restricted Stock Units
20 Aug 2026	Form 4: McCarthy Christopher, CFO & COO Received 277,009 shares by exercise or conversion · Granted 554,018 Restricted Stock Units · Granted 277,009 Stock Option (right to buy)
12 Aug 2026	8-K: Results of Operations and Financial Condition
10 Aug 2026	10-Q
22 Jul 2026	DRS
07 Jul 2026	DEFA14A
07 Jul 2026	Proxy statement: annual meeting on August 20, 2026 CEO pay $708K, up 0.6% · say-on-pay vote
25 Jun 2026	PREM14A

Comments